Salarius Pharmaceuticals Inc (NASDAQ: SLRX) embark on a clinical trial that seeks to investigate a novel lysine-specific demethylase 1 (LSD1) inhibitor called seclidemstat. This biopharmaceutical company has, over the years, focused n the development of working medicines to help out persons struggling with solid tumors,  pediatric cancers, and other cancers. Conducting […]